Similarly, Alpha-glucosidase inhibitors (AGI), commonly used to reduce glucose levels in T2DM [215], were found to increase the levels of EPCs (Sca-1+ Flk-1+) in a T2DM murine model, and improved the in vivo wound healing and angiogenesis through the Akt/eNOS signalling pathway [216]. Here, AKT1 is linked to type 2 diabetes mellitus.